吉西他滨与氟尿嘧啶联合顺铂二线治疗晚期食管鳞癌疗效比较  

Comparative analysis of gemcitabine or fluorouracil combined with cisplatin as second-line treatment of advanced esophageal squamous cell carcinoma

作　　者：闫晓杰[1] 夏学明 刘钦兰 房慧[1] 白莉[1] 

机构地区：[1]解放军总医院肿瘤内一科,北京100853

出　　处：《解放军医学院学报》2015年第6期607-610,共4页Academic Journal of Chinese PLA Medical School

摘　　要：目的比较吉西他滨和氟尿嘧啶类药物联合顺铂二线治疗晚期食管鳞癌的疗效和安全性。方法回顾性分析2013年1月-2014年10月解放军总医院收治的既往用紫杉类联合铂类一线化疗无效或进展后使用二线化疗方案（吉西他滨或者氟尿嘧啶类药物联合顺铂治疗）的患者的临床资料,分析其近期疗效、不良反应、远期疗效等。结果57例患者可评价疗效,吉西他滨组和氟尿嘧啶组的有效率分别为19.4%和19.2%,疾病控制率分别为58.1%和53.8%,中位无进展生存时间分别为3.0（2.39~3.69）个月和4.4（2.69~6.03）个月,中位总生存时间分别为6.0（4.87~7.21）个月和7.6（3.88~11.93）个月,差异均无统计学意义（P〉0.05）。两组患者不良反应易耐受,主要为骨髓抑制和恶心、呕吐。结论对于一线化疗无效或进展的晚期食管鳞癌患者,二线使用吉西他滨或者氟尿嘧啶类药物联合顺铂治疗有一定的疗效。Objective To observe and compare the efficacy and safety of gemcitabine or fluorouracil combined with cisplatin in the second-line treatment of advanced esophageal squamous cell carcinoma. Methods Clinical data about advanced esophageal squamous cell carcinoma （ESCC） patients from January 2013 to October 2014 who received gemcitabine or fluorouracil combined with cisplatin as second-line chemotherapy in our hospital after failure to chemotherapy were retrospectively analyzed, its adverse reactions and curative effect were evaluated. Results Fifty-seven patients were evaluated. The response rates were 19.4% and 19.2%, the disease control rates were 58.1% and 53.8%, the median progression-free survival （PFS） were 3.0 （2.39-3.69） months and 4.4 （2.69-6.03） months, and the median overall survival （OS） were 6.0 （4.87-7.21） months and 7.6 （3.88-11.93） months in gemcitabine group and fluorouracil group, respectively, with no significant difference （P 〉 0.05）. Toxicity was tolerable, and major adverse events were myelosuppression, nausea and vomiting in two groups. Conclusion Gemcitabine or fluorouracil combined with cisplatin as the second-line chemotherapy is effective in patients with advanced esophageal squamous cell carcinoma.

关 键 词：吉西他滨 氟尿嘧啶 化疗 食管肿瘤 鳞状细胞癌 

分 类 号：R735.1[医药卫生—肿瘤]